Compare Stocks: INBX, CRSP, DYN, and ACAD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.21 +2.7%	$24.39	$19.69 ▼ $29.48	$5.03B	0.81	1.68 million shs	1.78 million shs
CRSP CRISPR Therapeutics	$53.52 +3.6%	$52.37	$44.12 ▼ $78.48	$5.18B	1.74	1.66 million shs	1.28 million shs
DYN Dyne Therapeutics	$26.25 +1.4%	$22.00	$10.78 ▼ $27.09	$4.90B	1.07	2.64 million shs	1.99 million shs
INBX Inhibrx Biosciences	$88.66 +3.3%	$90.82	$20.55 ▼ $155.29	$1.30B	3.51	216,467 shs	407,679 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+12.91%	+10.60%	+30.40%	+22.73%
CRSP CRISPR Therapeutics	0.00%	+11.52%	-5.01%	-2.39%	-5.01%
DYN Dyne Therapeutics	0.00%	+4.25%	+8.16%	+49.06%	+126.49%
INBX Inhibrx Biosciences	0.00%	+8.06%	-14.63%	-34.01%	+322.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.21 +2.7%	$24.39	$19.69 ▼ $29.48	$5.03B	0.81	1.68 million shs	1.78 million shs
CRSP CRISPR Therapeutics	$53.52 +3.6%	$52.37	$44.12 ▼ $78.48	$5.18B	1.74	1.66 million shs	1.28 million shs
DYN Dyne Therapeutics	$26.25 +1.4%	$22.00	$10.78 ▼ $27.09	$4.90B	1.07	2.64 million shs	1.99 million shs
INBX Inhibrx Biosciences	$88.66 +3.3%	$90.82	$20.55 ▼ $155.29	$1.30B	3.51	216,467 shs	407,679 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+12.91%	+10.60%	+30.40%	+22.73%
CRSP CRISPR Therapeutics	0.00%	+11.52%	-5.01%	-2.39%	-5.01%
DYN Dyne Therapeutics	0.00%	+4.25%	+8.16%	+49.06%	+126.49%
INBX Inhibrx Biosciences	0.00%	+8.06%	-14.63%	-34.01%	+322.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.82	Moderate Buy	$33.44	14.49% Upside
CRSP CRISPR Therapeutics	2.58	Moderate Buy	$68.06	27.16% Upside
DYN Dyne Therapeutics	2.87	Moderate Buy	$34.42	31.11% Upside
INBX Inhibrx Biosciences	2.33	Hold	$150.00	69.19% Upside

Current Analyst Ratings Breakdown

Latest INBX, CRSP, DYN, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	CRSP CRISPR Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$55.00
8/6/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $37.00
8/5/2026	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$23.00 ➝ $25.00
8/5/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/5/2026	ACAD ACADIA Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$35.00 ➝ $36.00
8/4/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$82.00 ➝ $88.00
7/31/2026	DYN Dyne Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$47.00 ➝ $45.00
7/30/2026	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $35.00
7/29/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/29/2026	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.50

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.70	$0.89 per share	32.93	$7.58 per share	3.85
CRSP CRISPR Therapeutics	$3.51M	1,474.32	N/A	N/A	$18.06 per share	2.96
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$3.76 per share	N/A
INBX Inhibrx Biosciences	$1.30M	1,000.56	N/A	N/A	$0.55 per share	161.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	13.16	29.51	17.19	33.42%	9.03%	6.79%	N/A
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	8/10/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	N/A
INBX Inhibrx Biosciences	-$140.05M	-$8.39	N/A	N/A	N/A	N/A	-563.90%	-72.32%	8/12/2026 (Estimated)

Latest INBX, CRSP, DYN, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	N/A	N/A	N/A	N/A	N/A
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million
5/14/2026	Q1 2026	INBX Inhibrx Biosciences	-$1.6750	-$2.15	-$0.4750	-$2.15	N/A	N/A
5/11/2026	Q1 2026	DYN Dyne Therapeutics	-$0.7723	-$0.73	+$0.0423	-$0.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.48
CRSP CRISPR Therapeutics	0.34	17.85	17.96
DYN Dyne Therapeutics	0.28	12.02	12.02
INBX Inhibrx Biosciences	12.58	6.46	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
CRSP CRISPR Therapeutics	69.20%
DYN Dyne Therapeutics	96.68%
INBX Inhibrx Biosciences	82.46%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
CRSP CRISPR Therapeutics	5.20%
DYN Dyne Therapeutics	9.46%
INBX Inhibrx Biosciences	18.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
CRSP CRISPR Therapeutics	460	96.69 million	91.67 million	Optionable
DYN Dyne Therapeutics	100	186.75 million	169.08 million	Optionable
INBX Inhibrx Biosciences	166	14.67 million	11.99 million	Optionable

INBX, CRSP, DYN, and ACAD Headlines

Recent News About These Companies

Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold"

August 9 at 1:05 AM | marketbeat.com

Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday

August 5, 2026 | marketbeat.com

Swiss National Bank Invests $968,000 in Inhibrx Biosciences, Inc. $INBX

August 1, 2026 | marketbeat.com

Inhibrx Biosciences (NASDAQ:INBX) Downgraded by Wall Street Zen to Sell

August 1, 2026 | americanbankingnews.com

Inhibrx Biosciences (NASDAQ:INBX) Rating Lowered to Sell at Wall Street Zen

August 1, 2026 | marketbeat.com

Healthcare of Ontario Pension Plan Trust Fund Sells 93,300 Shares of Inhibrx Biosciences, Inc. $INBX

July 29, 2026 | marketbeat.com

Inhibrx Biosciences, Inc. $INBX Shares Bought by SummitTX Capital L.P.

July 27, 2026 | marketbeat.com

Inhibrx Biosciences: The Whole Story Rides On INBRX-106

July 25, 2026 | seekingalpha.com

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives Consensus Recommendation of "Hold" from Brokerages

July 20, 2026 | marketbeat.com

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

July 16, 2026 | prnewswire.com

Inhibrx Biosciences, Inc. Common Stock

July 13, 2026 | fxempire.comF

Inhibrx Biosciences (NASDAQ:INBX) Rating Increased to Hold at Wall Street Zen

July 12, 2026 | marketbeat.com

Inhibrx Biosciences (NASDAQ:INBX) Shares Down 7% - Here's What Happened

July 10, 2026 | marketbeat.com

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice

July 9, 2026 | zacks.com

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

June 15, 2026 | prnewswire.com

LifeSci Capital Reaffirms Their Buy Rating on Inhibrx Biosciences Inc (INBX)

May 18, 2026 | theglobeandmail.com

Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results

May 16, 2026 | finanznachrichten.de

Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study

May 16, 2026 | finance.yahoo.com

Inhibrx Reports First Quarter 2026 Financial Results

May 14, 2026 | prnewswire.com

Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study

May 11, 2026 | msn.com

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

May 11, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INBX, CRSP, DYN, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.21 +0.76 (+2.67%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$28.86 -0.36 (-1.22%)

As of 08/7/2026 07:59 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

CRISPR Therapeutics NASDAQ:CRSP

$53.52 +1.88 (+3.64%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$53.63 +0.11 (+0.21%)

As of 08/7/2026 07:48 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Dyne Therapeutics NASDAQ:DYN

$26.25 +0.37 (+1.43%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$26.08 -0.17 (-0.65%)

As of 08/7/2026 07:34 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Inhibrx Biosciences NASDAQ:INBX

$88.66 +2.87 (+3.35%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$87.56 -1.10 (-1.25%)

As of 08/7/2026 07:34 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INBX, CRSP, DYN, and ACAD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INBX, CRSP, DYN, and ACAD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INBX, CRSP, DYN, and ACAD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INBX, CRSP, DYN, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

CRISPR Therapeutics NASDAQ:CRSP

Dyne Therapeutics NASDAQ:DYN

Inhibrx Biosciences NASDAQ:INBX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INBX, CRSP, DYN, and ACAD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INBX, CRSP, DYN, and ACAD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INBX, CRSP, DYN, and ACAD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INBX, CRSP, DYN, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

CRISPR Therapeutics NASDAQ:CRSP

Dyne Therapeutics NASDAQ:DYN

Inhibrx Biosciences NASDAQ:INBX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools